Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy INmune Bio (INMB) stocks in Canada

Learn how to easily invest in INmune Bio stocks.

INmune Bio is a biotechnology business based in the US. INmune Bio stocks (INMB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.01 – the same closing value as a week prior. INmune Bio employs 5 staff and has a trailing 12-month revenue of around $28,916.

How to buy shares in INmune Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INMB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

INmune Bio stock price (NASDAQ:INMB)

Use our graph to track the performance of INMB stocks over time.

INmune Bio shares at a glance

Information last updated 2022-01-16.
Latest market close$8.78
52-week range$8.16 - $30.37
50-day moving average $11.75
200-day moving average $15.56
Wall St. target price$35.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.59

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy INmune Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

INmune Bio price performance over time

Historical closes compared with the close of $8.78 from 2022-01-21

1 week (2022-01-14) 8.78
1 month (2021-12-20) N/A
3 months (2021-10-22) -56.01%
6 months (2021-07-23) -58.31%
1 year (2021-01-22) -57.63%
2 years (2020-01-24) 75.78%
3 years (2019-01-20) N/A
5 years (2017-01-20) N/A

INmune Bio financials

Revenue TTM $28,916
Gross profit TTM $10,916
Return on assets TTM -19.38%
Return on equity TTM -36.88%
Profit margin 0%
Book value $4.95
Market capitalisation $156.7 million

TTM: trailing 12 months

INmune Bio share dividends

We're not expecting INmune Bio to pay a dividend over the next 12 months.

INmune Bio share price volatility

Over the last 12 months, INmune Bio's shares have ranged in value from as little as $8.16 up to $30.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INmune Bio's is 2.6553. This would suggest that INmune Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

INmune Bio overview

INmune Bio, Inc. , a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc. ; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc.

Stocks similar to INmune Bio

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site